Skip to main content
Mauna Kea Technologies logo

Mauna Kea Technologies — Investor Relations & Filings

Ticker · MKEA ISIN · FR0010609263 LEI · 5493007KMDG4MFIGJJ63 PA Manufacturing
Open in API
Filings indexed 774 across all filing types
Latest filing 2024-10-17 Earnings Release
Country FR France
Listing PA MKEA

About Mauna Kea Technologies

https://www.maunakeatech.com/en/

Mauna Kea Technologies is a medical device company that develops and markets the Cellvizio® platform, a real-time in vivo cellular imaging system. The platform utilizes Confocal Laser Endomicroscopy (CLE) technology, enabling physicians to visualize tissue at the cellular level during medical procedures. This "optical biopsy" is performed using flexible, miniature fiber-optic probes (Confocal Miniprobes™) that are compatible with standard endoscopes. The core function of Cellvizio® is to provide immediate microscopic visualization, which aids in accelerating diagnosis, informing treatment strategies, and improving the precision of therapeutic interventions. Key applications include gastroenterology (for conditions such as Barrett's esophagus and pancreatic cysts), interventional pulmonology (lung cancer diagnostics), urologic oncology, and neurosurgery. The technology supports enhanced surgical procedures, including real-time margin assessment, and is being integrated with robotic surgery and AI-assisted imaging systems.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Earnings Release Classification · 99% confidence The document is a press release dated October 17, 2024, announcing positive clinical results for the Cellvizio platform related to food intolerances and Irritable Bowel Syndrome (IBS). It details study findings, includes quotes from a professor and the CEO, and provides background information on IBS and the company. This format—a formal announcement of significant business/clinical news, often released before a full quarterly report—is characteristic of an Earnings Release (ER) or a general press release. Since it focuses on clinical data and strategic validation rather than just summarizing period-end financials (ER) or providing a full management discussion (MDA), and it is not a transcript (CT) or a formal regulatory filing like a 10-K, the most fitting category for a major, timely announcement of operational/clinical progress is the Earnings Release (ER), as these often accompany or precede quarterly financial reporting periods, or the Regulatory Filing (RNS) as a general announcement. Given the content is a detailed announcement of positive clinical data and strategic outlook, it functions as a key update. However, because it is a press release announcing clinical data and strategic direction, and not explicitly a summary of quarterly financial figures, it fits best under the general 'Regulatory Filings' (RNS) category if it's not a specific financial report, or potentially an Earnings Release (ER) if it's timed around a reporting cycle. Since it is a detailed announcement of clinical progress and market opportunity, and not a standard earnings summary, RNS is a safer general classification for non-standard announcements, but ER is often used for significant operational updates. Given the context of financial reporting databases, major announcements like this are often categorized as ER if they are timely updates, or RNS if they are purely operational/clinical. Since it is a formal announcement of results presented at a major congress, it is a significant corporate event announcement. I will classify it as an Earnings Release (ER) as these often contain operational highlights, or RNS as a fallback. Given the focus on clinical results and market strategy rather than just financial figures, RNS is the most appropriate general category for a non-standard, material announcement, though ER is plausible if this is tied to a Q3 update cycle. I will lean towards RNS as the best fit for a material, non-standard press release. Q4 2024
2024-10-17 French
Inside Information / News release on accounts, results
Earnings Release Classification · 100% confidence The document explicitly states it announces 'financial results for the first half 2024, ended June 30, 2024' and provides detailed, unaudited financial tables covering H1 2024 and Q3 2024 performance. This content structure—comprehensive financial review for a period shorter than a year (six months)—is characteristic of an Interim/Quarterly Report. Although it contains elements of an Earnings Release (ER) by summarizing key highlights, the depth of the financial tables and management discussion points towards a more comprehensive interim report. It is not a full Annual Report (10-K). The document also mentions the 'half-year financial report is available on the Company's website,' but since the text provided *is* the detailed report content, it should be classified as the report itself, not just the announcement (RPA). Therefore, 'Interim / Quarterly Report' (IR) is the most appropriate classification. H1 2024
2024-10-15 English
Informations privilégiées / Communiqué sur comptes, résultats
Earnings Release Classification · 100% confidence The document is titled "Mauna Kea Technologies publie ses résultats financiers du S1 2024 et ses ventes du T3 2024" (Mauna Kea Technologies publishes its H1 2024 financial results and Q3 2024 sales). It contains detailed financial tables for the first semester (S1 2024) and the third quarter (T3 2024), including income statements, revenue breakdowns, and operational highlights. This structure is characteristic of a comprehensive financial report covering a period shorter than a full year, specifically a half-year report. The text explicitly mentions the 'rapport financier semestriel est disponible' (the semi-annual financial report is available) and presents the figures as 'non auditées' (unaudited). This strongly points to an Interim/Quarterly Report (IR), as it is a comprehensive report for a period shorter than a year (H1 2024). It is not an Earnings Release (ER) because it is a detailed report, not just highlights, and it is not a 10-K as it covers only H1/Q3, not the full year. H1 2024
2024-10-15 French
Rapports financiers et d'audit semestriels/examens réduits / Rapport financier semestriel
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Rapport Financier Semestriel 2024' (Semi-annual Financial Report 2024) and contains comprehensive financial statements, including a consolidated income statement, balance sheet analysis, management discussion of results, and operational highlights for the first half of the year. It is a substantive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2024
2024-10-15 French
Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Monthly information regarding the total number of voting rights and shares comprising the share capital" and references French regulatory articles (Commercial Code, AMF General Regulations). It provides a table detailing the number of shares and voting rights as of September 30, 2024. This specific type of periodic disclosure regarding the total share capital and voting rights is a mandatory regulatory filing in many jurisdictions, often related to capital structure changes or mandatory disclosures. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the most relevant as it deals directly with the number of shares and voting rights, which are fundamental components of the capital structure. While it is a regulatory filing, 'SHA' is more specific than the general 'RNS'. The document is short and contains the actual data, not just an announcement of a report, so RPA/RNS is less appropriate than the specific content code.
2024-10-04 English
Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "Information relative au nombre total de droits de vote et d'actions composant le capital social" (Information relative to the total number of voting rights and shares comprising the share capital) and cites French regulations (Article L233-8-II du Code du Commerce, Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers - AMF). It provides a table detailing the number of shares and total voting rights as of September 30, 2024, and mentions recent share issuance. This specific type of mandatory disclosure in France, detailing the total number of shares and voting rights, is typically classified as a notification related to capital structure or share movements. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the most appropriate fit as it directly relates to the total number of shares and capital structure updates, even though it's a periodic disclosure rather than a primary issuance announcement. It is not a general earnings release (ER), a full annual report (10-K), or a director's dealing (DIRS). Given the content focuses strictly on the total share count and voting rights, SHA is the best classification.
2024-10-04 French

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.